takuro wada , o sato, a kawai, t hasegawa sapporo medial university , sapporo japan
DESCRIPTION
Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas: A Clinicopathological Study of 281 Cases. Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan National Cancer Center, Tokyo Japan. Purpose. - PowerPoint PPT PresentationTRANSCRIPT
![Page 1: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/1.jpg)
Expression of EGFR, ERRB2, and Expression of EGFR, ERRB2, and KIT in Adult Soft Tissue Sarcomas:KIT in Adult Soft Tissue Sarcomas:
A Clinicopathological Study of 281 CasesA Clinicopathological Study of 281 Cases
Takuro Wada, O Sato, A Kawai, T HasegawaSapporo Medial University, Sapporo JapanNational Cancer Center, Tokyo Japan
![Page 2: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/2.jpg)
Purpose
To analyze expression patterns of EGFR, ERBB2, and KIT on 281 patients with common adult STS by standard immunohistochemical technique on formalin-fixed, paraffin-embedded sections
To Verify whether a significant association with prognosis is present
![Page 3: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/3.jpg)
Patients
281 adult patients with common soft tissue sarcomas in the extremities and trunk diagnosed and treated at the NCC, Tokyo, Japan
Histologic subtypeFibrosarcoma (FS) 11Leiomyosarcoma (LMS) 11 Myxoid liposarcoma ( LSM) 52Well differentiated liposarcoma ( LSW) 50MPNST 18Myxofibrosarcoma (MFS) 53Pleomorphic MFH (PMFH) 44Synovial sarcoma (SS) 42
![Page 4: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/4.jpg)
Characteristic of 281 patients
Gender: 152 females and 129 males Age: 10 to 85 years (median 50 yrs) Treatment:
Resection All patientsRadiotherapy 25Chemotherapy 37Chemo + Radi 23
![Page 5: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/5.jpg)
Pathology reviewing, grade and Staging Tumor typing
WHO Classification of Soft Tissue Tumors Histologic grade
Differentiation, necrosis, MIB-1 index TNM staging classification
![Page 6: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/6.jpg)
Primary Antibodies
Antibody Source Dilution Positive control
EGFR, mouse monoclonal
DakoCytomation,
Clone 2-18C9
Prediluted Breast ca
ERBB2, rabbit polyclonal
DakoCytomation 1:500 Breast ca
KIT, rabbit polyclonal
DakoCytomation 1:50 Mast cell
![Page 7: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/7.jpg)
0
1+or ≤ 10% = Negative
2+
3+and >10% = Positive
Strength Distribution
Evaluation of staining
![Page 8: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/8.jpg)
Results
![Page 9: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/9.jpg)
Immunohistochemical Pattern
Histologic type No. EGFR
Fibrosarcoma 11 4 (36%)
Leiomyosarcoma 11 8 (73%)
Myxoid liposarcoma 52 3 (6%)
Well-D liposarcoma 50 19 (38%)
Myxofibrosarcoma 53 16 (89%)
MPNST 18 47 (89%)
PMFH 44 39 (89%)
Synovial sarcoma 42 32 (76%)
Total 281 168 (60%)
![Page 10: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/10.jpg)
Immunohistochemical Pattern
Histologic type No. EGFR ERBB2 KIT
Fibrosarcoma 11 4 (36%) 0 0
Leiomyosarcoma 11 8 (73%) 0 0
Myxoid liposarcoma 52 3 (6%) 0 0
Well-D liposarcoma 50 19 (38%) 0 0
Myxofibrosarcoma 53 16 (89%) 0 0
MPNST 18 47 (89%) 0 0
PMFH 44 39 (89%) 0 0
Synovial sarcoma 42 32 (76%) 3 2
Total 281 168 (60%) 3 2
![Page 11: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/11.jpg)
Diffuse EGFR (2+) in leiomyosarcoma
Diffuse EGFR (3+) in MPNST
![Page 12: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/12.jpg)
Diffuse EGFR (3+) in spindle cells of biphasic synovial sarcoma
Focal ERBB2 (2+) in epithelioid cells of biphasic synovial sarcoma
![Page 13: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/13.jpg)
Focal KIT (2+) in spindle cells of monophasic synovial sarcoma
![Page 14: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/14.jpg)
Overall survival curves for EGFR
N=281 P=0.03
month
706050403020100
Ove
rall
surv
ival
1.0
.8
.6
.4
.2
0.0
EGFR (+)
EGFR (-)79%
64%
![Page 15: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/15.jpg)
Variables associated with patient survival: Univariate analysis Stage Histological grade Depth Size Positive EGFR staining
![Page 16: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/16.jpg)
Variables associated with patient survival: Multivariate analysis Stage Histological grade Depth Size Positive EGFR staining
![Page 17: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/17.jpg)
706050403020100
1.0
.8
.6
.4
.2
0.0706050403020100
1.0
.8
.6
.4
.2
0.0
Kaplan-Meier survival curves stratified by EGFR status and by tumor size
Size 5-10cm (n=135) Size>10cm (n=77)
EGFR-EGFR-
EGFR+
EGFR+
p=0.03 p=0.06
![Page 18: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/18.jpg)
706050403020100
1.0
.8
.6
.4
.2
0.0706050403020100
1.0
.8
.6
.4
.2
0.0
Kaplan-Meier survival curves stratified by EGFR status and by histological grade
Grade 2 (n=74) Grade 3 (n=111)
EGFR-
EGFR-
EGFR+
EGFR+
p=0.08 p=0.7
![Page 19: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/19.jpg)
Discussion
![Page 20: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/20.jpg)
Expression of EGFR in STSs
Authors Cases Positive Subtype
Gusterson et al. (1985) 35 18 (51%) MFH, SS, Epi
Perosio et al. (1989) 40 20 (50%)
Duda et al. (1993) 43 21(49%)
Barbashina (2002) 19 13 (68%) SS
Nielsen (2002) 42 18 (52%) SS
This study 281 170 (60%)
MFH, SS, MPNST
![Page 21: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/21.jpg)
Expression of ERBB2 and KIT
Merimsky et al. (2002)No overexpression of ERBB2 in 230 STSs
Hornick et al. (2002)Very limited expression of KIT in 365 STSs
This studyLimited expression of ERBB2 and KIT
![Page 22: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/22.jpg)
Overall survival curves for EGFR
N=281 P=0.03
month
706050403020100
Ove
rall
surv
ival
1.0
.8
.6
.4
.2
0.0
EGFR (+)
EGFR (-)79%
64%
![Page 23: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/23.jpg)
IMC-C225ABX-EGFTyrosine kinase inhibitor
Irresa
Target-specific agents and approaches for anticancer therapy
![Page 24: Takuro Wada , O Sato, A Kawai, T Hasegawa Sapporo Medial University , Sapporo Japan](https://reader035.vdocument.in/reader035/viewer/2022062722/56813ad7550346895da31a16/html5/thumbnails/24.jpg)
Conclusion
We analyzed the expression of EGFR, ERBB2, and KIT in 281 patients with STS
Positive staining of EGFR: 168/281 (60%) Positive staining of ERBB2, KIT was limited EGFR overexpression was a negative
prognostic factor associated with histological grade